When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

The anti-HER2 agent trastuzumab has improved outcomes for breast cancer patients with HER2-overexpressing tumours. However, systemic treatment for patients with HER2-negative disease is yet limited to endocrine and cytotoxic therapies. The increasing avail of the anthracyclines and taxanes in early sheet disease has reduced the available therapeutic options for patients with relapsed disease, and options are besides resident for patients with triple-negative tumours, who typically bear a dangerous prognosis. The novel agents bevacizumab and ixabepilone get recently been approved for metastatic breast cancer and mucho other agents are currently in clinical elaborating that may contribute very valuable therapeutic options.

Keywords: